Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutrient label comments

This article was originally published in The Tan Sheet

Executive Summary

FDA extends to April 30 the deadline for comments on its proposed rulemaking concerning percent daily value information allowed on nutrition facts and supplement facts labels. The agency published an advanced notice of PRM on Nov. 2, 2007 with a 90-day comment period but extended the deadline following a request. Dietary supplement industry stakeholders say the proposal to use estimated average requirements to set daily values for the labels could reduce existing values and lead to lower nutrient levels in food (1"The Tan Sheet" Nov. 12, 2007, p. 3)...

You may also be interested in...



Industry Speaks Up Against Using EARs To Set Daily Nutrient Values

Dietary supplement industry stakeholders contend an FDA proposal to use estimated average requirements to set daily values for nutrition and supplement facts labels could reduce existing values and lead to lower nutrient levels in food

Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs

Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.

QUOTED. 24 February 2020. Daniel Taddeo.

Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.

Topics

UsernamePublicRestriction

Register

PS101328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel